| HIG |
Report |
Core EPS (adj., diluted) |
MISS |
pred ~$3.05 vs. cons ~$3.19 |
MEDIUM |
| HIG |
Report |
P&C headline combined ratio (Business + Personal blended) |
MISS |
pred ~93.0 vs. cons ~90.8 (higher ratio = worse profitability) |
MEDIUM |
| HIG |
Report |
Net investment income (pre-tax) |
BEAT |
pred ~$770M vs. cons ~$745M |
HIGH |
| HIG |
Guide |
FY2026 P&C catastrophe load / current-accident-year cat assumption |
UNCHANGED |
guide ~5.5% of NPE unchanged vs. cons ~5.5% (FY2026) |
LOW |
| HIG |
Guide |
Q3 2026 share repurchase pace |
UNCHANGED |
guide ~$450M/quarter vs. cons ~$450M (Q3 2026) |
MEDIUM |
| HIG |
Guide |
Business Insurance expense ratio glide path (sub-30% target) |
UNCHANGED |
guide ~29.5%-29.8% exit vs. cons ~29.8% (FY2026 exit) |
MEDIUM |
| HIG |
Guide |
Employee Benefits core earnings margin |
LOWER |
guide ~7.0%-7.5% vs. cons ~8.0% (FY2026) |
MEDIUM |
| HIG |
Guide |
Full-year 2026 net investment income growth |
BETTER |
guide ~+8%-10% y/y vs. cons ~+6% y/y (FY2026) |
MEDIUM |
| HIG |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.8% |
— |
MEDIUM |
| HIG |
Return |
5-day cumulative residual |
-2.8% (FOLLOW-THROUGH) |
A cat-driven EPS miss against a stock that has already rallied ~10% off its June lows into the print (like TRV's post-beat sell-the-news reaction on valuation/downgrades) sets up limited room for a relief rally even if underlying combined ratios and NII are solid. Out-period math works against the stock: analysts will likely trim FY26 EPS to reflect the incremental cat charge (which flows through the full-year cat budget even if within the aggregate-treaty attachment), while lingering overhangs (legacy abuse reserve trend, soft group-disability/PFML margins, decelerating ex-comp BI pricing) give sell-side more reason to shade estimates down rather than back-fill the miss with a 'one-time cat' narrative, producing continued mild downward drift over the week rather than an immediate rebound. |
LOW |